PLSEHealthcare · Medical Instruments & SuppliesThe 6 Wall Street analysts covering Pulse Biosciences, Inc. hold a median 12-month price target of $59 — +10.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 38 of 100 as at 26 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Pulse Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (99): The shares have been drifting up relative to others.
Quality (11): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on PLSE, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +10.9% from it.
Of the 20 most recent actions, 3 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 13 Oct 2026 | Oppenheimer | Maintains | Outperform | $35 → $60 |
| 6 Oct 2026 | Canaccord Genuity | Maintains | Buy | $43 → $58 |
| 23 Sept 2026 | BTIG | Initiates | Buy | — |
| 23 Sept 2026 | BTIG | Initiates | Buy | $70 |
| 9 Sept 2026 | Freedom Capital Markets | Initiates | Buy | $73 |
| 9 Sept 2026 | Freedom Capital Markets | Initiates | Buy | — |
| 17 Aug 2026 | Needham | Initiates | Buy | $58 |
| 17 Aug 2026 | Needham | Initiates | Buy | — |
| 10 Aug 2026 | Canaccord Genuity | Maintains | Buy | $32 → $43 |
| 10 Aug 2026 | Canaccord Genuity | Maintains | Buy | — |
| 4 June 2026 | Canaccord Genuity | Initiates | Buy | $32 |
| 4 June 2026 | Canaccord Genuity | Initiates | Buy | — |
| 7 July 2025 | Oppenheimer | Initiates | Outperform | — |
| 21 Sept 2022 | Maxim Group | Downgrade | Hold | — |
| 13 May 2022 | HC Wainwright & Co. | Downgrade | Neutral | — |
| 1 Apr 2022 | HC Wainwright & Co. | Maintains | Buy | — |
| 1 Apr 2022 | Stephens & Co. | Maintains | Overweight | — |
| 10 Feb 2022 | HC Wainwright & Co. | Maintains | Buy | — |
| 16 Nov 2021 | HC Wainwright & Co. | Maintains | Buy | — |
| 27 July 2021 | Stephens & Co. | Initiates | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
PLSE appears in the Radar on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 27 Oct 2026, Pulse Biosciences, Inc. returned +204.0% against +13.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 98% of US stocks
Cheaper than 1% of US stocks
Cheaper than 3% of US stocks
Cheaper than 94% of US stocks
Higher than 48% of US stocks
Higher than 45% of US stocks
Higher than 3% of US stocks
Higher than 10% of US stocks
Higher than 16% of US stocks
Higher than 9% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Pulse Biosciences, Inc. has a market value of $3.8B and an enterprise value of $3.7B.
Revenue in the twelve months to 30 June 2026: $1.2M. The latest quarter grew 8.2% year on year.
Net income over the same four quarters: −$80.1M, a −6755.8% net margin.
Diluted earnings per share, trailing twelve months: $−1.18.
Free cash flow in the twelve months to 30 June 2026: −$61.4M.
Trailing P/E: −49.0×; forward P/E: −45.3× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Pulse Biosciences, Inc. employs 116 people — $10K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Pulse Biosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Pulse Biosciences said it will report its third-quarter 2026 business updates and financial results after market close on November 5, 2026. Management will host a conference call that day at 1:30 p.m. PT / 4:30 p.m. ET.
Why it matters — PLSE watchers can note the scheduled date and time for the company’s quarterly update and management discussion.
Pulse Biosciences announced a partnership with the Clayman Thyroid Center at the Hospital for Endocrine Surgery in Tampa. The arrangement covers commercial use of its nPulse Vybrance Percutaneous Electrode System and a clinical collaboration.
Why it matters — The partnership involves both use of Pulse Biosciences’ system in patient treatment and clinical collaboration at a thyroid center.
Pulse Biosciences announced equity inducement awards for two new employees. The awards were granted outside the company’s 2017 Equity Incentive Plan under its 2017 Inducement Equity Incentive Plan.
Why it matters — The grants represent equity compensation associated with the hiring of two new employees.
Pulse Biosciences announced that its latest nPulse technology advancement will be featured at the 21st Annual International Ventricular Arrhythmias Symposium, taking place October 9–10, 2026, in New York. The presentation will cover preclinical applications of two nPulse prototype devices.
Why it matters — The symposium presentation provides PLSE watchers with an update on the company’s nPulse technology and its preclinical applications.
Pulse Biosciences announced that its NANOPULSE-AF pivotal clinical study reached its enrollment target of 164 evaluable patients across 15 clinical sites. The study is evaluating the nPulse Cardiac Catheter System for atrial fibrillation treatment.
Why it matters — Reaching the enrollment target marks a milestone in the clinical study of PLSE’s nPulse cardiac catheter system.
The 6 Wall Street analysts covering Pulse Biosciences, Inc. have a median 12-month price target of $59, with estimates ranging from $55 to $73. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 6 analysts covering Pulse Biosciences, Inc., 6 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Pulse Biosciences, Inc. 38 out of 100 across roughly 4,600 US stocks as at 26 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 26 Oct 2026, Pulse Biosciences, Inc. ranks 38 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (99 of 100).
No one can know that. What the data says: the median 12-month target from 6 analysts implies +10.9% from the last close, and Ticker Nerd's factor model ranks Pulse Biosciences, Inc. 38 out of 100 as at 26 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Pulse Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PLSE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $55 to $73 over the next 12 months.
Pulse Biosciences, Inc. returned +204.0% over the 12 months to 27 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Pulse Biosciences Inc is a bioelectric medicine company focused on developing and commercializing medical technologies that use proprietary pulsed-field energy to treat targeted cells while preserving surrounding tissue. Its current product portfolio includes the nPulse System for benign skin lesions, the nPulse Vybrance Percutaneous Electrode system for soft tissue ablation, the nPulse Cardiac Surgical Clamp for atrial fibrillation procedures, the nPulse Cardiac Catheter System for circumferential cardiac ablation, and the nPulse Console, a software-enabled platform designed to support physician workflows.
The most recent item we track (Business Wire, 22 Oct 2026): "Pulse Biosciences Schedules Third Quarter 2026 Financial Results Conference Call for November 5, 2026". Pulse Biosciences said it will report its third-quarter 2026 business updates and financial results after market close on November 5, 2026. Management will host a conference call that day at 1:30 p.m. PT / 4:30 p.m. ET.
Pulse Biosciences Inc is a bioelectric medicine company focused on developing and commercializing medical technologies that use proprietary pulsed-field energy to treat targeted cells while preserving surrounding tissue. Its current product portfolio includes the nPulse System for benign skin lesions, the nPulse Vybrance Percutaneous Electrode system for soft tissue ablation, the nPulse Cardiac Surgical Clamp for atrial fibrillation procedures, the nPulse Cardiac Catheter System for circumferential cardiac ablation, and the nPulse Console, a software-enabled platform designed to support physician workflows. The company serves healthcare providers across dermatology, surgical soft-tissue care, and cardiac electrophysiology, with applications centered on minimally invasive treatment approaches. Pulse Biosciences Inc positions itself within the medical device market through its proprietary energy-based platform, which is designed for clinical use in areas where precise cellular targeting is important.
CEO Mr. Paul Arthur LaViolette M.B.A. · 116 employees · United States · https://www.pulsebiosciences.com
